{
  "screen_failure_rates": {
    "diabetes": {
      "overall": 0.55,
      "by_criterion": {
        "hba1c_range": {
          "description": "HbA1c outside specified range",
          "screen_failure_rate": 0.25,
          "typical_range": "7.0-11.0%",
          "optimized_range": "7.5-10.5%",
          "optimization_impact": "+0.05 to +0.08 improvement in screen success"
        },
        "egfr_threshold": {
          "description": "eGFR below threshold",
          "screen_failure_rate": 0.15,
          "typical_threshold": "> 60 mL/min",
          "optimized_threshold": "> 30 mL/min",
          "optimization_impact": "+0.12 to +0.18 improvement in screen success"
        },
        "bmi_criteria": {
          "description": "BMI outside acceptable range",
          "screen_failure_rate": 0.08,
          "typical_range": "18.5-45 kg/mÂ²",
          "notes": "Upper limit more commonly restrictive"
        },
        "concomitant_medications": {
          "description": "Prohibited concomitant medications",
          "screen_failure_rate": 0.12,
          "notes": "Insulin washout periods common cause"
        },
        "cardiovascular_history": {
          "description": "Recent cardiovascular events",
          "screen_failure_rate": 0.10,
          "typical_exclusion": "MI/stroke within 6 months",
          "optimization": "Consider 3 months for stable patients"
        }
      }
    },
    "oncology": {
      "overall": 0.60,
      "by_criterion": {
        "performance_status": {
          "description": "ECOG performance status",
          "screen_failure_rate": 0.20,
          "ecog_0_1_eligible": 0.65,
          "ecog_0_2_eligible": 0.85,
          "impact_of_expanding": "+0.15 to +0.20 screen success rate"
        },
        "laboratory_values": {
          "description": "Laboratory out of range",
          "screen_failure_rate": 0.18,
          "common_issues": ["neutropenia", "thrombocytopenia", "elevated liver enzymes"],
          "mitigation": "Consider lower thresholds for non-myelosuppressive agents"
        },
        "brain_metastases": {
          "description": "Active brain metastases",
          "screen_failure_rate": 0.08,
          "notes": "Allowing stable treated lesions could improve enrollment 5-10%"
        },
        "prior_therapy": {
          "description": "Prior therapy washout or limits",
          "screen_failure_rate": 0.12,
          "notes": "Prior immunotherapy restrictions common cause"
        },
        "organ_dysfunction": {
          "description": "Organ dysfunction (renal, hepatic)",
          "screen_failure_rate": 0.15,
          "notes": "Often most restrictive criterion in elderly"
        }
      }
    },
    "cardiovascular": {
      "overall": 0.45,
      "by_criterion": {
        "age_limits": {
          "description": "Age outside specified range",
          "screen_failure_rate": 0.10,
          "typical_upper_limit": "75-80 years",
          "impact_of_removing": "+0.15 screen success in elderly populations"
        },
        "blood_pressure": {
          "description": "Blood pressure out of range",
          "screen_failure_rate": 0.12,
          "typical_range": "90-180 mmHg systolic",
          "notes": "White coat hypertension contributes to false exclusions"
        },
        "concomitant_cv_meds": {
          "description": "Concomitant cardiovascular medications",
          "screen_failure_rate": 0.08,
          "notes": "Anticoagulant restrictions common"
        },
        "renal_function": {
          "description": "Impaired renal function",
          "screen_failure_rate": 0.15,
          "common_in": "Heart failure trials with elderly patients"
        }
      }
    }
  },
  "enrollment_rates": {
    "by_phase": {
      "phase_1": {
        "healthy_volunteers": {
          "subjects_per_site_per_month": 4.0,
          "screen_success_rate": 0.65
        },
        "patient_population": {
          "subjects_per_site_per_month": 1.5,
          "screen_success_rate": 0.35
        }
      },
      "phase_2": {
        "subjects_per_site_per_month": 2.0,
        "screen_success_rate": 0.40,
        "typical_enrollment_duration_months": 12
      },
      "phase_3": {
        "subjects_per_site_per_month": 1.5,
        "screen_success_rate": 0.35,
        "typical_enrollment_duration_months": 18
      }
    },
    "by_therapeutic_area": {
      "diabetes": {
        "screen_success_rate": 0.45,
        "dropout_rate": 0.15,
        "enrollment_rate_per_site_per_month": 1.8
      },
      "oncology": {
        "screen_success_rate": 0.40,
        "dropout_rate": 0.20,
        "enrollment_rate_per_site_per_month": 1.5
      },
      "cardiovascular": {
        "screen_success_rate": 0.55,
        "dropout_rate": 0.12,
        "enrollment_rate_per_site_per_month": 2.2
      },
      "rare_disease": {
        "screen_success_rate": 0.25,
        "dropout_rate": 0.10,
        "enrollment_rate_per_site_per_month": 0.5
      }
    }
  },
  "optimization_benchmarks": {
    "successful_optimizations": [
      {
        "trial_type": "Type 2 Diabetes",
        "modification": "Widened HbA1c range from 7.0-11.0% to 7.5-10.5%",
        "screen_success_before": 0.32,
        "screen_success_after": 0.41,
        "impact": "+28% relative improvement"
      },
      {
        "trial_type": "Type 2 Diabetes",
        "modification": "Lowered eGFR threshold from >60 to >30 mL/min",
        "screen_success_before": 0.35,
        "screen_success_after": 0.48,
        "impact": "+37% relative improvement"
      },
      {
        "trial_type": "Oncology",
        "modification": "Expanded ECOG from 0-1 to 0-2",
        "screen_success_before": 0.28,
        "screen_success_after": 0.38,
        "impact": "+36% relative improvement"
      },
      {
        "trial_type": "Oncology",
        "modification": "Allowed stable treated brain metastases",
        "screen_success_before": 0.30,
        "screen_success_after": 0.36,
        "impact": "+20% relative improvement"
      },
      {
        "trial_type": "Heart Failure",
        "modification": "Removed upper age limit of 80 years",
        "screen_success_before": 0.42,
        "screen_success_after": 0.52,
        "impact": "+24% relative improvement"
      }
    ],
    "optimization_targets": {
      "screen_success_rate": {
        "target": ">= 0.35",
        "action_threshold": "< 0.25",
        "excellent": ">= 0.50"
      },
      "enrollment_rate": {
        "target": ">= 2.0 subjects/site/month",
        "action_threshold": "< 1.0 subjects/site/month"
      },
      "time_to_complete": {
        "target": "<= 120% of planned duration",
        "action_threshold": "> 150% of planned duration"
      }
    }
  },
  "complexity_impact": {
    "criteria_count_impact": {
      "less_than_10": {
        "complexity": "Low",
        "estimated_screen_success": 0.50,
        "risk": "May be overly broad; verify scientific rigor"
      },
      "10_to_20": {
        "complexity": "Medium",
        "estimated_screen_success": 0.40,
        "risk": "Optimal range for most trials"
      },
      "20_to_30": {
        "complexity": "High",
        "estimated_screen_success": 0.30,
        "risk": "May limit enrollment; review for consolidation"
      },
      "greater_than_30": {
        "complexity": "Very High",
        "estimated_screen_success": 0.20,
        "risk": "Significant enrollment barriers; optimization recommended"
      }
    },
    "category_distribution_impact": {
      "laboratory_heavy": {
        "definition": "> 30% of criteria are laboratory-based",
        "impact": "May increase screen failures by 10-15%",
        "mitigation": "Review if all laboratory parameters are essential"
      },
      "exclusion_heavy": {
        "definition": "Exclusion criteria > 2x inclusion criteria count",
        "impact": "May indicate overly restrictive design",
        "mitigation": "Review exclusions for scientific necessity"
      },
      "subjective_language": {
        "definition": "> 5 criteria contain subjective terms",
        "impact": "Increases variability and protocol deviations",
        "mitigation": "Provide objective definitions"
      }
    }
  }
}
